Pfizer vs Merck & Co.
PFE
Pfizer Inc. NYSE
$24.05 ▼ 2.71%
VS
MRK
Merck & Co., Inc. NYSE
$120.67 ▲ 0.89%
Last updated: (1m ago) • PFE at $24.05, MRK at $120.67
CleaRank Financial AI • Data from TwelveData & CoinGecko
Reviewed by CleaRank editorial team. Data refreshed daily. Not financial advice.
Comparative Analysis
MRK wins due to superior operational efficiency, robust profitability metrics, and clear technical momentum. While PFE struggles with a depressed valuation and weak technical positioning, MRK demonstrates consistent strength in both its core business and market performance. Investors should favor MRK for its higher return on equity and superior net profit margins, which signal a more effective capital allocation strategy. PFE currently faces significant headwinds, reflected in its proximity to 52-week lows and a lack of clear upward momentum. Consequently, MRK offers a more compelling risk-adjusted profile for institutional portfolios in the current market environment.
Key Differentiator
The decisive factor is the disparity in capital efficiency, specifically the ROE gap of over 10 percentage points in favor of MRK. While PFE is priced as a value position, it lacks the operational excellence required to justify a long-term holding. MRK's ability to consistently generate higher returns on its asset base makes it the superior choice for institutional capital.
Joint Outlook
The 6-12 month outlook for MRK remains bullish, with the potential to test new highs if it maintains its current margin trajectory. We expect MRK to continue outperforming the sector as it leverages its strong asset base to drive consistent earnings. Conversely, PFE faces a challenging 6-12 months, with the stock likely to remain range-bound until it can demonstrate a clear catalyst for margin improvement. A failure to hold current support levels could lead to further downside for PFE, making it a 'wait and see' candidate for institutional investors.
Price Analysis Comparison
Valuation Metrics
| Metric | PFE | MRK |
|---|---|---|
| P/E Ratio | 19.15 | 32.05 |
| Market Cap | 140.89B | 298.03B |
| Price/Sales | 2.26 | 4.27 |
| Price/Book | 1.59 | 6.13 |
| EV/EBITDA | 7.66 | 11.00 |
| Dividend Yield | N/A | N/A |
MRK trades at a premium with a P/E of 32.05, reflecting market confidence in its growth trajectory and operational stability. In contrast, PFE's P/E of 19.15 suggests a market that is pricing in significant uncertainty or stagnant growth prospects. While PFE appears cheaper on a headline basis, the valuation gap is justified by the stark disparity in profitability and return metrics. Investors are paying a higher multiple for MRK because it consistently delivers higher margins and better capital efficiency. PFE's lower multiple acts as a value trap until the company can demonstrate a meaningful turnaround in its core revenue drivers.
Profitability & Efficiency
| Metric | PFE | MRK |
|---|---|---|
| Rev. Growth (Qtly) | 5.40% | 4.90% |
| Profit Margin | 11.83% | 13.59% |
| Return on Equity | 8.31% | 18.94% |
| Return on Assets | 5.69% | 12.58% |
| Debt/Equity | 71.60 | 106.94 |
MRK dominates in capital efficiency, boasting a net profit margin of 13.59% compared to PFE's 11.83%. The disparity in return on equity is even more pronounced, with MRK delivering 18.94% against PFE's 8.31%. This indicates that MRK is far more effective at generating profit from shareholder capital. Furthermore, MRK's return on assets of 12.58% doubles that of PFE, highlighting superior management of the company's asset base.
Earnings Reality Check
PFE
Analysis loading...
MRK
Analysis loading...
Technical Indicators
| Indicator | PFE | MRK |
|---|---|---|
| RSI (14) | 34.46 | 62.24 |
| 50-Day MA | $26.09 | $115.52 |
| 200-Day MA | $25.87 | $105.90 |
MRK is in a clear uptrend, trading well above both its 50-day ($115.52) and 200-day ($105.90) moving averages. With an RSI of 62.24, the stock maintains strong bullish momentum without being overextended. Conversely, PFE is in a precarious position, trading below both its 50-day ($26.09) and 200-day ($25.87) moving averages, which now act as significant overhead resistance. The RSI of 34.46 for PFE indicates oversold conditions, yet the lack of a positive MACD crossover suggests that buyers are not yet stepping in to defend these levels.
AI Analyst Sentiment
PFE
Hold
Technical Score: 55/100
MRK
Buy
Technical Score: 68/100
Institutional sentiment heavily favors MRK, as evidenced by its price action near 52-week highs and consistent technical strength. Smart money is likely rotating into MRK for its defensive qualities and reliable margin expansion. PFE is currently experiencing negative sentiment, with the stock hovering near its 52-week low of $23.11. The lack of institutional support for PFE is reflected in its inability to reclaim key moving averages despite its lower valuation.
Risk Stratification
| Metric | PFE | MRK |
|---|---|---|
| Beta (Volatility) | 0.30 | 0.22 |
| Sharpe Ratio | -0.20 | -0.11 |
PFE faces the risk of continued multiple compression if it fails to improve its net profit margins and ROE. The stock is currently testing critical support levels, and a breach of the $23.11 floor could trigger further institutional liquidation. Additionally, PFE's reliance on specific product cycles makes it vulnerable to competitive pressures that could further erode its already thin margins. The primary risk for PFE is a prolonged period of stagnation that keeps the stock range-bound or in a downtrend. MRK's primary risk is its higher valuation, which leaves it susceptible to a pullback if the broader market experiences a correction or if the company misses earnings expectations. Given its premium, any sign of slowing growth could lead to a rapid repricing of the stock. However, MRK's strong fundamentals provide a more robust cushion against these risks compared to PFE.
Comparative ProTips
- Always prioritize ROE and Net Profit Margin over headline P/E when comparing pharmaceutical peers.
- Use moving average crossovers as the primary trigger for entry, especially when a stock is trading below its 200-day SMA like PFE.
- Avoid 'value traps' where a low P/E is simply a reflection of declining operational efficiency.
Monte Carlo Projection (10yr)
Actionable Trade Plans
Compare entry, exit, and risk management levels for both assets
Select Your Trade Bias
Risk Tolerance
Conservative 3% Aggressive
Portfolio Value
$ ✎
Position Size: $200 - $300 per asset
PFE
Current: $24.05
ENTRY ZONES
Conservative
$22.85
Aggressive
$24.05
RISK MANAGEMENT
STOP LOSS
$22.16
MAX LOSS
-3%
Volatility-Adjusted Stop Loss
Calculated based on volatility and technical support levels.
Profit Targets (Based on Conservative)
+5%
$23.99
+10%
$25.13
+15%
$26.27
MRK
Current: $120.67
ENTRY ZONES
Conservative
$114.64
Aggressive
$120.67
RISK MANAGEMENT
STOP LOSS
$111.20
MAX LOSS
-3%
Volatility-Adjusted Stop Loss
Calculated based on volatility and technical support levels.
Profit Targets (Based on Conservative)
+5%
$120.37
+10%
$126.10
+15%
$131.83
Calculate Your Trade
ℹ️ Disclaimer
This comparison involves assets with varying risk profiles. The content is for educational purposes only. Identifying the stronger asset is based on relative strength (RS) and technical convergence. Past correlation does not guarantee future lockstep movement. Trading involves risk of loss. Note: The AI favored MRK based on current technical setup. This is valid for the specified timeframe only.